NCT01042782已完成1 期
Phase I Study of Daily RAD001 Administered Orally in Combination With Mitomycin C, Administered Every Three Weeks to Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction
Krankenhaus Nordwest1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C
研究概览
简要总结
Patients with advanced gastric cancer are treated with a combination of RAD001 (everolimus) and Mitomycin C.
详细描述
The purpose of this monocenter, single-arm, phase I trial is to determine the maximum-tolerated-dose, dose-limiting toxicity (DLT) and preliminary efficacy and safety of RAD001 in combination with Mitomycin C in patients with advanced gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 prior platin containing chemotherapy in the palliativ setting or progressive disease under adjuvant or neoadjuvant therapy within 6 months of treatment start date.
- •Histological evidence of advanced or metastatic gastric cancer or cancer of the esophageal junction.
- •At baseline CT or MRI scan must demonstrate measurable disease by RECIST criteria, i.e., the presence of at least one measurable lesion. Measurable disease lesions must be accurately measured in at least one dimension with longest diameter > 20 mm using conventional techniques or > 10 mm with spiral CT scan (with minimum lesion size no less than double the slice thickness).
- •At least one measurable lesion outside of the field of any prior radiation therapy (according to RECIST criteria). Prior radiotherapy to a single index lesion is not allowed.
- •Adult male or female patients (≥18 years of age).
- •Patients must have disease not amenable to surgery, radiation, or combined modality therapy with curative intent.
- •ECOG 0 or 1
- •Life expectance >4 months
- •Adequate bone marrow function, renal function, liver function
- •Women using an acceptable form of contraception prior to receiving RAD001 or women who meet the protocol definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy.
- •Fully recovered from any previous surgery, prior chemotherapy or radiation therapy (at least 4 weeks since major surgery or prior myelosuppressive chemotherapy). With the exception of alopecia, patients must have resolution of all acute toxic effects of any prior surgery, radiotherapy, or chemotherapy to NCI CTC (Version 2.0) grade <=
- •Patients with rapidly progressive tumors (upon the decision of the investigator) can be treated <4 weeks since last chemotherapy, if they fully recovered from all side effects.
- •Signed informed consent
排除标准
- •Anticancer therapy within 3 weeks of enrollment including chemotherapy, hormonal therapy, immunotherapy, or radiotherapy. Patients with rapidly progressive tumors (upon the decision of the investigator) can be treated <4 weeks since last chemotherapy, if they fully recovered from all side effects.
- •Prior therapy with RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus).
- •Patients treated with Mitomycin C
- •No neurotoxicity >= grade 2 CTC
- •No gastric or intestinal obstruction
- •Patients taking drugs known to inhibit or induce isoenzyme CYP3A
- •Patients with any concurrent major medical condition liable to compromise the patient's participation in the study (e.g known HIV infection, uncontrolled diabetes, serious cardiac dysrhythmia or condition, New York Heart Association classification of III or IV, congestive cardiac failure, myocardial infarction within 6 months, unstable angina, chronic or acute renal or liver disease, uncontrolled serious infections including abscess or fistulae, etc.)
- •Patients with a history of another malignancy prior to study entry, except curatively treated non-melanotic skin cancer or carcinoma in-situ cervical cancer unless in complete remission or no evidence of disease and off all therapy for that disease for a minimum of 5 years
- •No symptomatic brain metastasis.
- •Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
- •Female patients who are pregnant or breast feeding
- •History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
- •History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
研究组 & 干预措施
RAD-MitC
Experimental
RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
干预措施: RAD001 and MitomycinC (Drug)
结局指标
主要结局
maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C
时间窗: every week
次要结局
- preliminary efficacy of RAD001 in refractory gastric cancer. Efficacy is defined as complete response or partial response at 12 weeks based on RECIST-criteria(every 6 weeks)
- progression-free survival (PFS)(every 6 weeks)
- overall survival (OS)(every three months)
- safety and tolerability of the combination of RAD001 and Mitomycin C as assessed by frequency, severity, and duration of treatment-related adverse effects(every week)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOXAdvanced Gastric CancerNCT01049620Asan Medical Center40
已完成
1 期
Study of Everolimus (RAD001) in Combination With LenalidomideSolid Organ MalignanciesAdenoidcystic CarcinomaNeuroendocrine TumorsNCT01218555Emory University44
Unknown
1 期
Everolimus (RAD001) in Elderly Patients With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT00636922Bayside Health40
已完成
1 期
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck CancerHead and Neck CancerNCT00858663Memorial Sloan Kettering Cancer Center13
已完成
2 期
Safety Study of RAD001 to Treat Patients With Metastatic Kidney CancerCarcinoma, Renal CellNCT00446368The Methodist Hospital Research Institute66